Abstract: Arsenic trioxide (As 2 O 3 ; ATO) is considered to be one of the most potent drugs in cancer chemotherapy and is highly effective in the treatment of acute promyelocytic leukemia (APL). It is well established that treatment of APL patients with ATO is associated with the disappearance of the PML-RAR fusion transcript, the characteristic APL gene product of the chromosomal translocation t(15;17). Although its mode of action is still not fully understood, ATO is known to induce cell apoptosis via generation of reactive oxygen species and activation of caspases. Several reports have indicated that ATO acts principally by inducing cell apoptosis not only in APL, but in a variety of non-APL cells including myeloma cells, chronic myeloid leukemia cells and cells of immune origin, including B or T lymphocytes, macrophages and, more recently, neutrophils. There is an increasing amount of data, including some from our laboratory, concerning the interaction between ATO and human primary cells. The focus of this review will be to cover the role of ATO in human immune primary cells with special emphasis on cells of myeloid origin.
INTRODUCTION

Generalities
Inorganic arsenic is a widely distributed pollutant in soil and water. For example, millions of humans are exposed worldwide to this environmental toxicant through contaminated drinking water [1] . Paradoxically, arsenic compounds have been used in traditional oriental medicine to treat a variety of diseases other than cancers, such as inflammatory diseases, including rheumatoid arthritis [2, 3] . Subsequently, some of these pure chemicals were used in medicine but because of their toxic and oncogenic effects, their therapeutic use was abandoned for several years. It was only in the 1970s that arsenic agents were found to be highly effective for treating several types of leukemia [3] . It was documented later that the principal mode of action of arsenic was via its ability to induce apoptosis in leukemia cells [4, 5] . More recently, arsenic compounds, especially arsenic trioxide (As 2 O 3 or ATO), have received renewed attention. To date, ATO is considered to be one of the most potent drugs for chemotherapy of cancers [5] [6] [7] [8] and there is no doubt that this drug is very effective in the treatment of various cancers, especially of acute promyelocytic leukemia (APL) [3, 4, 6] . In the past few years, several studies have indicated that ATO acts principally by inducing cell apoptosis not only in APL, but in a variety of cells including non-APL acute myeloid leukemia cells, myeloma cells, chronic myeloid leukemia cells and various solid tumor cells [9] [10] [11] [12] [13] . In addition, ATO was found to induce apoptosis in a variety of myeloid cell lines including NB4, HL-60, PLB-985 and U937, and in some immune cells such as B and T lymphocytes [14] [15] [16] [17] and monocytic cells. Curiously, the effect of ATO on polymorphonuclear neutrophil (PMN) cell apoptosis had never been studied prior to our own recent interest in this area [18] , *Address correspondence to this author at the Université du Québec, INRSInstitut Armand-Frappier, 531 Boul. des Prairies, Laval, QC, H7V 1B7, Canada; Tel: (450) 687-5010, Ext. 8847; Fax: (450) 686-5309; E-mail: denis.girard@iaf.inrs.ca despite the fact that these cells are key players in inflammation. Moreover, the possibility that ATO induced neutrophil apoptosis was neglected, though neutropenia, although not frequent, has been reported following cancer therapy, resulting in recurrent infections in patients. Also, an immunotoxicological study reported that neutropenia was marked after exposure to arsenic compounds [19] and in a phase II study of ATO in patients with relapsed or refractory multiple myeloma, 67% of the patients experienced neutropenia [12] . Finally, in another phase II trial, 11/16 multiple myeloma patients treated with ATO developed cytopenia, five associated with infectious complications [13] . Based on these observations, we hypothesized and recently confirmed that ATO can induce apoptosis in mature human neutrophil cells [18] . This review will explore the role of ATO in primary cells, with a special emphasis on cells of human myeloid origin, including monocytic and neutrophil cell populations. This will prefaced by a brief discussion of ATO activity in cancer cells.
Activity of ATO in Cancer Cells
Mode of Action
ATO is well known for its ability to induce cell apoptosis via caspases and reactive oxygen species (ROS) [4, 15, [20] [21] [22] [23] [24] . Of note, the involvement of mitochondria in ATOinduced cell apoptosis is still a subject of debate [14] . ATO inhibits the release of cytochrome c, a component highly involved in caspase activation and cell apoptosis. The cytoskeleton, especially the microtubules, is an important cellular target for arsenic, probably due to the high sulfhydryl protein content of cytoskeletal components [23, 25] . The toxicity of ATO is partly explained by its ability to bind and inactivate several sulfhydryl-containing proteins and enzyme systems [23] . ATO induces cell differentiation when used at a low concentration (ranging between 0.5-5 μM), while it induces cell apoptosis at concentrations ranging from 5-20 μM in a variety of cell lines [4, 7, 9, 24] . Interestingly, the concentrations used in the majority of in vitro studies are in the range of clinically achievable concentrations [17, 25] .
Cell Signaling Pathways
ATO is known to activate the mitogen-activated protein kinase (MAPK) pathway in a variety of cancer cells. For example, ATO-induced U937 cell apoptosis was found to be dependent on activation of p38 and inactivation of extracellular signal-regulated kinase (ERK)-1/2 [26] . The p38 mitogen-activated protein kinase pathway was also involved in ATO-induced apoptosis of human APL NB-4 cells, K562 CML-blast crisis cell line as well as in the MCF-7 human breast carcinoma and the LNKAP prostate carcinoma cell lines [27] . The p38-dependent proapoptotic activity of ATO in chronic myelogenous leukemia K562 cells was confirmed in at least one other study [28] . Activation of c-jun Nterminal kinase (JNK) also occurs in ATO-induced apoptosis in APL [29, 30] . Recently, it was demonstrated that ATO could down-regulate survivin, a member of the inhibitor of apoptosis (IAP) family that is highly expressed in various cancer cells, via activation of both p38 and JNK in apoptotic human lung adenocarcinoma cell line H1355 [31] . Thus, ATO can act by modulating all three major MAPK pathways, namely p38, Erk-1/2 and JNK, depending on the cell types and experimental conditions.
INTERACTION ARSENIC TRIOXIDE-PRIMARY CELLS
An impressive number of studies on the role of ATO in cancer cell lines or in immature cancer cells isolated from patients have been published in the last two decades. In contrast, the role of ATO in primary non cancer cells has received little attention. Although it is beyond the scope of the present review to cover all studies focussing on the role of ATO in primary cells, the sections bellow will briefly describe the effect of arsenic trioxide in diverse primary cells of non immune origin. The final sections will review in greater detail the role of ATO in cells of immune origin, particularly human myeloid cells.
Effect of Arsenic in Primary Cells of Non Immune Origin
In 1996, Barchowsky and colleagues reported that chronic exposure of porcine endothelial cells to low levels of environmentally-derived arsenic induced oxidant stress and activation of NF-B transcription factor [32] . Later, they found that low concentrations of ATO caused cell proliferation associated with an increase in superoxide (O 2 -) and hydrogen peroxide (H 2 O 2 ) accumulation, as well as an increase in Src kinase activity, an H 2 O 2 -dependent tyrosine phosphorylation [33] . Interestingly, these concentrations of ATO were insufficient for activating MAPKs, whereas p38 MAPK was activated at higher concentrations causing cell death. In one other study aimed at understanding the potential mechanism of renal toxicity of ATO, human primary renal cortical cells were treated with ATO in order to conduct a geneexpression analysis using DNA microarrays. ATO treatment altered expression of more than 70 genes was observed, 17 of which were upregulated in a time-dependent manner by ATO, including genes involved in heme oxidation and stress response (HMOX1, MAPK1), induction of apoptosis (BAX), cell proliferation (H41), acute phase response and cell adhesion (FN1), etc. [34] . Recently, treatment of primary normal human keratinocytes with arsenic led to an increase in p53 and its binding to DNA, triggering a sustained activation of the PI3K/PKB/glycogen synthase kinase-3 beta pathway [35] . This was found to drive the cells into a celldifferentiated stage in which the proliferation signals were depressed. Based on epidemiological studies which reported a high association between inorganic arsenic exposures and vascular diseases, Tsou and colleagues employed primary porcine aortic endothelial cells and investigated regulatory mechanisms in cell cycle arrest induced by arsenite [36] . They found that arsenite increased cell proliferation at low concentrations (1 and 3μM) whereas high concentrations (10, 20 or 30μM) inhibited cell proliferation, correlating with an increase in G2/M phase arrest accompanied by accumulation and/or phosphorylation of p53, Cdc25B, Cdc25c and securin [36] .
Effects of Arsenic in Primary Cells of Immune Origin
Non Myeloid Cells
The effects of arsenic derivatives in combination with a variety of compounds have been investigated in lymphocytes in vitro, but not extensively. Thus, the role of ATO alone has not been the central object of immune cell physiology. Nevertheless, in 1993, biphasic effects of ATO on DNA synthesis in human lymphocytes were reported [37] . At very low concentrations, ATO was found to enhance DNA synthesis in human lymphocytes stimulated by phytohemagglutinin, whereas higher concentrations were found to inhibit this response. Gupta and colleagues (2003) demonstrated that ATO can induce apoptosis in CD4+ and CD8+ human T cells by enhancing oxidative stress and by down regulating the expression of the antiapoptotic Bcl-2 protein [11] . In a recent study investigating the role of ATO in NK cell-mediated cytotoxicity, ATO was found to up-regulate NKG2D ligands in various cancer cell lines, such as K562 chronic myelogenous leukemic cells, NB4 acute promyelocytic leukemic cells and MCF7 breast cancer cells, increasing their susceptibility against NK cells, and suggesting that the immunomodulatory property of ATO would be an attractive strategy to improve the effectiveness of NK cell-based cancer immunotherapy [38] .
Myeloid Cells
Monocytes-Macrophages
Only recently (2006), ATO was reported to alter human monocyte and macrophage cell physiology [39, 40] . Lemarie et al. demonstrated that incubation of macrophages with a low concentration of 1 μM ATO for 6 days induced a rapid cell rounding after 8h and a subsequent loss of adhesion associated with a marked reorganization of the actin cytoskeleton [39] . When monitoring typical macrophage cell surface markers by flow cytometry, ATO markedly reduced expression of the integrins CD11b and CD29, known to be involved in macrophage adhesion and spreading. The expression of CD71, a well-known macrophagic differentiation factor, was also reduced by the ATO treatment. In contrast, the cell surface expression of CD14, the typical marker of human blood monocytes, was increased. Interestingly, the expression of CD11c was unaffected in these experiments, indicating that ATO does not alter the general cell surface expression of macrophage markers. Because one of the major biological functions of macrophages is to exert phagocytosis, the effect of ATO on endocytosis and phagocytosis was investigated, and ATO significantly decreased both responses [39] . ATO was also found to potentiate LPS-induced IL-8 and TNF-cytokine production, indicating that it not only directly affects macrophages, but also interferes with other macrophage agonists. The fact that ATO alters macrophage endocytosis and phagocytosis could partly explain why arsenic treated-mice were found to be less effective at clearing a S. aureus infection than control mice [41] . Interestingly, in this latter study, murine macrophages from arsenic-treated mice also showed decrease chemotactic migration.
In one other study [40] , ATO induced human monocyte apoptosis during macrophagic differentiation by a mechanism involving caspases [40] . Furthermore, they found that the decreased binding of the p65 subunit of NF-B in monocytes could be responsible for this pro-apoptotic effect. Indeed, transfection of promonocytic cell line U937 with a p65 retroviral expressing vector attenuated ATO-induced apoptosis in differentiating monocytes. Induction of apoptosis by ATO was related to down-regulation of XIAP and FLIP L , two key antiapoptotic players regulated by NF-B. More recently, ATO significantly increased O 2 -production in blood monocyte-derived macrophages in a time-dependent fashion when incubated in the presence of 1 μM ATO for 72h [42] . Using pharmacological inhibitors, the authors demonstrated that such O 2 -production occured mainly via the Rho Kinase/p38-kinase pathway. To support the involvement of the NADPH oxidase complex in ATO-induced human primary macrophages, the authors demonstrated that ATO induced membrane translocation of p47 phox , p67 phox and Rac1 which normally occurs during NADPH oxidase activation. Using a blocker of the NADPH enzymatic complex assembly, the plant-derived phenol apocynin, they demonstrated that the translocation of p47 phox was prevented [42] . In addition, O 2 -production was completely inhibited by apocynin and a specific Rac1 inhibitor, NSC-23766. Interestingly, another argument supporting the role of NADPH oxidase on the ATO-induced O 2 -production was the observation that the kinetics of reactive oxygen species production were similar to those of p47 phox translocation.
These observations and results clearly indicate that human monocytes and macrophages are targets for ATO, and that this compound possesses potent immunotoxic effects. The other cell type of myeloid origin that is important in innate immunity and inflammation is the neutrophil. The status of information regarding ATO-human neutrophil interactions is summarized in the following section.
Polymorphonuclear Neutrophils (PMNs)
For the past few years, we have been interested in investigating the mode of action of several compounds which modulate human neutrophil apoptosis, an important biological process involved in the resolution of inflammation. Essentially, resolution of inflammation occurs following elimination of apoptotic PMNs by professional phagocytes, including macrophages. PMNs are primordial players of innate immunity and provide a very effective defense against bacterial and fungal infections. They are terminally mature nondividing cells which develop in the bone marrow from CD34+ stem cells. Following a series of cell divisions, they mature into myeloblasts, promyelocytes, myelocytes, metamyelocytes, band neutrophils and finally, mature neutrophils. Many PMNs are released from the bone marrow; this number has been estimated at 5 x 10 10 cells per day in a normal adult [1, 2] . Cell turnover must therefore be under strict control, and these cells are known to spontaneously undergo apoptosis. This may explain why the number of PMNs remains relatively stable in healthy individuals. Although not frequent, neutropenia has been found to occur in cancer patients following treatment with ATO. This observation prompted us to investigate the possibility that this anticancer drug could also directly induce PMN apoptosis. ATO was found to induce neutrophil apoptosis in a concentrationdependent manner by a caspase-dependent mechanism, since its proapoptotic effects were reversed by addition of the pancaspase z-VAD-fmk inhibitor [18] . More specifically, we demonstrated that 5 μM ATO activates caspase-3 and caspase-8. Interestingly, because ATO is known to act via induction of ROS production [11, 20, 21, 24] , we investigated the possibility that ATO induced O 2 -production in human PMNs via NADPH activation and found that this was not the case. Cells were responsive, since treatment with phorbol 12-myristate 13 acetate (PMA) significantly increased O 2 -production. This was unexpected, since NADPH is the major source of ROS production in PMNs. We then examined whether or not ATO could induce apoptosis at the same potency in wildtype promyelocytic PLB-985 cells and in PLB-985 cells deficient in gp91 phox , which are unable to produce ROS via NADPH activation [47] . ATO induced apoptosis at the same potency in both cell types, indicating that ROS are produced by other routes. Because we have previously described cytoskeletal protein degradation during apoptosis of human granulocytes, including neutrophils [43] , promyelocytes [44, 45] and eosinophils [46] , we investigated whether or not ATO could induce such degradation. We found that the microfilament-associated protein gelsolin, as well as the intermediate filament proteins lamin B 1 andtubulin were cleaved in ATO-induced human PMNs [18] . Despite the fact that we did not observe O 2 -production in ATO-induced neutrophils, we pre-incubated cells with catalase, known to degrade H 2 O 2 , before treating them with ATO. We found that not only was the ability of ATO to induce neutrophil apoptosis reversed, but its ability to induce cleavage of gelsolin, lamin B 1 and -tubulin was also reversed. In addition, catalase treatment also reversed ATOinduced caspase-3 and caspase-8 activities, as well as de novo protein synthesis [18] . Interestingly, although ATO is known to target microtubules in a variety of cells, this study was the first to demonstrate that not only microtubules, but other cytoskeletal structures, including microfilaments and intermediate filaments, are also targets of ATO treatment in human neutrophils.
As previously mentioned, the identification of new neutrophil proapoptotic agents is important for potential use in down-regulating inflammation. Once such agents have been identified, it is important to elucidate their modes of action. When compared to other neutrophil proapoptotic molecules, ATO possesses a unique feature: it induces de novo protein synthesis, an event that is normally exclusive to antiapoptotic agents, including cytokines (GM-CSF, IL-4, IL-15) and other agents, such as sodium butyrate and dexamethasone [48] [49] [50] [51] [52] [53] . Intriguingly, dexamethasone is normally a proapoptotic agent in a variety of cells, but it delays apoptosis in neutrophils [52] . In order to better understand the mode of action of ATO, we initiated a proteomic approach to identify which proteins were de novo synthesized in response to ATO. We suspected that these newly synthesized proteins were implicated in the proapoptotic activity of ATO, since pre-treatment of cells with cycloheximide, a protein synthesis inhibitor, largely attenuated the effects of ATO [18] . Following 2D-SDS-PAGE, we identified one spot as annexin-1 (442631-NCBI) by NanoLC-MS/MS using the Q-Tof Ultima (Waters) mass spectrometer [54] . We confirmed this by immunoprecipitating newly synthesized annexin-1 (ANXA1) from metabolically-labeled neutrophil cell lysates. For most scientists, the word "annexin" is strictly directly linked to annexin-V, because of its ability to bind acid phospholipids in the presence of calcium used to detect phosphatidylserine externalization (flip-flop) on the surface of apoptotic cells, including apoptotic human neutrophils. However, annexins are a family of ubiquitous proteins, of which 20 members are currently known [55, 56] . Interestingly, more than 20 years ago, ANXA1, the first characterized member of this family of proteins able to bind (i.e. to annex), was found to be a glucocorticoid (GC)-inducible protein largely responsible for the anti-inflammatory properties of GCs, particularly in asthma. Since then, ANXA1 has been the object of several studies, which established that its powerful antiinflammatory activity is due largely to its ability to inhibit cytosolic phospholipase A 2 (cPLA 2 ), which plays a key role in the production of prostaglandins and leukotrienes known as potent inflammatory mediators [57] . The fact that ANXA1 had been identified previously as a neutrophil proapoptotic molecule, when added exogenously, was of major interest to us [58] . Using ANXA1-KO mice, we initiated experiments with neutrophils devoid of ANXA1 in order to investigate the role of this protein in ATO-induced neutrophil apoptosis. Surprisingly, ATO induced apoptosis at the same potency, regardless of the ANXA1 levels, refuting a major role of this protein in ATO-induced neutrophil apoptosis. We then identified another newly-synthesized protein in response to ATO in human neutrophils as heat-shock protein (HSP) 89 [54] . Consequently, we investigated the possibility that ATO could induce a HS-like response in human neutrophils. We found that both heat shock and ATO treatments induced gene expression of HSP89 , HSP70 and HSP27. Interestingly, ANXA1 has been reported to have some chaperone-like function [59] and to be a stress protein induced by heat, H 2 O 2 and sodium arsenite [60] .
Although we demonstrated that ATO induced human neutrophil apoptosis, its mode of action required further elucidation. Moreover, its role in other neutrophil functions had never been investigated prior to our recent study [61] . In this study, ATO activated p38 and JNK but not the Erk-1/2 in human neutrophils. We initiated this study by investigating the potential activation of p38, since this kinase is known to be involved in stress response. Interestingly, the ability of ATO to activate p38 in neutrophils was not reversed by catalase, indicating that ATO activates p38 independently of H 2 O 2 production. We had previously documented that ATO did not induce O 2 -production via NADPH activation [18] in neutrophils, but that pretreatment with catalase inhibited apoptosis and de novo protein synthesis, indicating that another source of H 2 O 2 must be responsible. Other experiments revealed that ATO induced ROS, but these were only detectable after 1h of treatment, using flow cytometry with cells labeled with H 2 DCFDA, indicating that ATO-induced p38 activation occurs before ROS generation [61] . Knowing that ATO activated both p38 and JNK, we then investigated their involvement in apoptosis. Using pharmacological inhibitors, we found that ATO-induced neutrophil apoptosis occurred via a MAPK-independent mechanism. Thus, we suspected that MAPKs were involved in other neutrophil responses. We found that the ability of ATO to enhance neutrophil adhesion, migration, phagocytosis, release and activity of gelatinase, and degranulation of secretory, specific and gelatinase (but not azurophilic granules) occurred by a p38 and/or JNK mechanism(s). This study was the first to establish that ATO could induce neutrophil responses other than apoptosis [61] . Fig. (1) summarizes how ATO affects human neutrophil functions and the known mechanisms involved.
CONCLUSION AND PERSPECTIVES
The above observations clearly indicate that several primary cells are targets of ATO and that the diverse biological effects and modes of action are not fully understood. It is highly predictable that the interaction of ATO with primary cells will become a more active area of research in the near future. ATO is known particularly for its clinical use in acute promyelocytic leukemia. Since this drug kills promyelocytes by apoptosis, it is receiving more attention in the treatment of other type of cancers, either used alone or in combination with other molecules. The studies performed with primary cells clearly indicate that ATO has the uses for treatment of other diseases. The fact that ATO can target myeloid cells such as monocytic and neutrophil cell populations opens the possibility of using this drug for regulation of inflammation. Some of our results conducted in human neutrophils, in which we found that ATO enhanced phagocytosis, appear contradictory to those performed by Lemarie and colleagues using macrophages. They reported that ATO inhibits phagocytosis; however it is important to mention that the concentration and kinetics of cell stimulation were quite different. It would be interesting, therefore, to verify whether or not macrophages treated with 5μM ATO for 30-60 minutes (instead of several days) give the same results as those we observed in neutrophils. This is one of only several examples which indicate that further studies need to be performed with primary cells in order to better understand the mode of action of ATO. We believe that in the near future, elucidation of the signalling events involved in myeloid cells activated by ATO will provide a better comprehension of the mechanisms involved in their activation, thereby assisting in the improvement and development of therapeutic tools for the treatment of inflammatory diseases. Based on the observations and results presented in this review, especially those conducted with human neutrophils, we believe that ATO represents a very promising potential anti-inflammatory molecule for use in the treatment and/or improvement of inflammatory disorders, including certain cancers which are accompanied by inflammation. Because studies investigating the role of ATO in myeloid cells, including neutrophils, are recent and incomplete, future data will help for better elucidating potential usefulness of ATO for treating diseases other than cancers, including inflammatory disorders. Fig. (1) . Activation of human neutrophils by arsenic trioxide. When freshly isolated human polymorphonuclear neutrophils (PMNs) are incubated in the presence of clinically achievable concentration (5 μM) of arsenic trioxide (ATO), several observations could be made over time. For example, after 20-24h of incubation, more than 80% of cells are in apoptosis. Few hours before, caspase activation and cytoskeleton breakdown occurred and this could be visualized by cleavage of several cytoskeletal proteins, including gelsolin, lamin B 1 and -tubulin. Pre-treatment of cells with the pan caspase inhibitor z-VAD-FMK, or with the H 2 O 2 inhibitor catalase, reversed almost completely both apoptosis and cytoskeleton breakdown. ATO also induces de novo protein synthesis of several polypeptides including annexin-1 (ANXA1) and some heat shock proteins (HSP), the role of which are still unclear. Pre-treatment of cells with the potent protein synthesis inhibitor cycloheximide (CHX) attenuated neutrophil apoptosis. After few minutes of activation (1-30 min), ATO induces cell signalling events in PMNs, including activation of the two MAPKs p38 and JNK, but not Erk-1/2. These two kinases are involved in the ability of ATO to enhance neutrophil adhesion and migration, whereas only p38 appears to be involved in ATO-induced phagocytosis and degranulation. Interestingly, the three MAPKs are not involved in the proapoptotic effect of ATO.
